RecruitingNot applicableNCT07090668
Trans-auricular Nerve Stimulation as an Innovative Approach to the Treatment of Pain in Pediatric Patients Suffering From Sickle Cell Disease
Studying Genetic hemoglobinopathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Emory University
- Principal Investigator
- Anna Woodbury, MD, MD, MPHEmory University
- Intervention
- tAN device(device)
- Enrollment
- 20 enrolled
- Eligibility
- 7-18 years · All sexes
- Timeline
- 2025 – 2026
Study locations (1)
- Children's Hospital of Atlanta: Eagelston, Atlanta, Georgia, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07090668 on ClinicalTrials.govOther trials for Genetic hemoglobinopathy
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07488091Multi Disciplinary Sickle Cell Disease Obstetrics Care Program in GhanaUniversity of Ghana Medical School
- RECRUITINGNANCT07316478Stress Management and Mindfulness Intervention for Patients With Sickle Cell DiseaseUniversity of Pennsylvania
- RECRUITINGNANCT07188766Efficacy of Liberal Versus Restricted IV Fluid Approach in the Management of Sickle Cell Vaso-Occlusive CrisisImam Abdulrahman Bin Faisal University
- RECRUITINGPHASE1NCT07087262A Phase I Study of SNH-119014 in Healthy VolunteersScinnoHub Pharmaceutical Co., Ltd.
- RECRUITINGNANCT06886477Sickle Cell, Pain and Mediterranean DietUniversity of Illinois at Chicago
- RECRUITINGNANCT06367192School Readiness Intervention for Preschool Children With Sickle Cell DiseaseSt. Jude Children's Research Hospital
- RECRUITINGNANCT06735625Pilot Study "AHSP as a Biomarker of Sickle Cell Disease in a Population of Adults and Children"Centre Hospitalier de Saint-Denis
- RECRUITINGPHASE1, PHASE2NCT06144749A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD)Hillhurst Biopharmaceuticals, Inc.